Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Neoadjuvant for Stage III NSCLC (PILOT)
NCT06357598Phase 4Recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Jan 2024
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by The Affiliated Hospital of Qingdao University. Started Jan 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06357598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06357598.